#ESMO26 | TALAPRO-3: Patient-reported outcomes comparing talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC.

Back to meeting Original

Back to meeting

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-23 20:45· 2 days agoScore45

talazoparib

Body

#ESMO26 | TALAPRO-3: Patient-reported outcomes comparing talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC.

An important perspective on quality of life with PARP inhibitor combinations.

@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily

36 views · 0 likes · 1 repost · 0 replies

Conference abstracts

2219RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta

https://esmocongress.esmo.org

Source: Martin ZapataLaguado · x.com